NCT07179380View on ClinicalTrials.gov

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

344

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

December 30, 2028

Conditions

Pulmonary HypertensionInterstitial Lung Disease

Interventions

DRUG

Treprostinil Palmitil Inhalation Powder

Oral inhalation using a capsule-based dry powder inhaler device.

DRUG

Placebo

Oral inhalation using a capsule-based dry powder inhaler device.

All Listed Sponsors

lead

Insmed Incorporated

INDUSTRY

NCT07179380 - Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Biotech Hunter | Biotech Hunter